Status:

COMPLETED

Treatment CLI Nonrevascularizable Lower Limb With Cell Therapy

Lead Sponsor:

Instituto de Investigación Hospital Universitario La Paz

Collaborating Sponsors:

Hospital Universitario La Paz

Conditions:

Nonrevascularizable Critical Ischemia of the Lower Limbs

Eligibility:

All Genders

18-80 years

Phase:

PHASE1

PHASE2

Brief Summary

It has been demonstrated the feasibility, safety and effectiveness of mesenchymal stem cells derived from lipoaspirate for treating various pathologies fistula. With this project we will address a stu...

Detailed Description

The primary endpoint of safety and feasibility study will be done when the patient has received treatment at 12 months after implantation. It defines that the process is safe when in the development a...

Eligibility Criteria

Inclusion

  • Informed Consent.
  • \> 18 years.
  • Chronic arterial ischemia grades IV-V of Rutherford that affects at least one limb.
  • Arterial occlusion direct flow or distal femoropopliteal level.
  • No option for surgical or endovascular revascularization.
  • Life expectancy exceeding two years.
  • High probability of need for major amputation at 6 months (CLI nonrevascularizable).
  • Negative pregnancy test if applicable.

Exclusion

  • Background of hematologic neoplasia or unresolved.
  • Hipertensión uncontrolled blood (\> 180/110).
  • Severe heart Insuficiencia (New York Heart Association \[NYHA\] IV) or ejection fraction \<30%.
  • Malignant ventricular, Arritmias.
  • Trombosis of deep vein the past three months.
  • active infection.
  • Infarto infarction or stroke the previous three months.
  • Medical or psychiatric illness of any kind which, in the opinion of the investigator, may be a reason for exclusion from the study.
  • Subjects with congenital or acquired immunodeficiencies. Hepatitis B and / or C or tuberculosis diagnosed at the time of inclusion, treponema.
  • Major surgery or severe trauma of the subject in the previous semester.
  • Administration of any investigational drug at present to three months prior to enrollment for this trial.
  • Pulmonary heart disease, in the opinion of the investigator, be unstable or is sufficiently serious to dismiss the patient from the study.
  • Infants or pregnant women.
  • Adult women of childbearing potential not using effective contraception during the trial

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2015

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT01824069

Start Date

April 1 2013

End Date

September 1 2015

Last Update

June 15 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Universitario La Paz

Madrid, Madrid, Spain, 28046